# Clinical Effects and Safety of Zhi Sou San for Cough: A Meta-Analysis of Randomized Trials

Authors: Ningchang Cheng; Jia Zhu; Pinpin Ding
Journal: Evidence-Based Complementary and Alternative Medicine
 (2017)

---

## Abstract

Introduction. Zhi Sou San (ZSS), a traditional Chinese prescription, has been widely applied in treating cough. The purpose of this meta-analysis was to evaluate the effectiveness and safety of ZSS for cough.Methods. We searched relevant articles up to 5 March 2017 in seven electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PubMed, Chinese National Knowledge Infrastructure (CNKI), Cqvip Database (VIP), China Biology Medicine disc (CBM), and Wanfang Data. Randomized controlled trials (RCTs) were eligible, regardless of blinding. The primary outcome was the total effective rate.Results. Forty-six RCTs with a total of 4007 participants were identified. Compared with western medicine, ZSS significantly improved the total effective rate (OR: 4.45; 95% CI: 3.62–5.47) and the pulmonary function in terms of FEV1 (OR: 0.35; 95% CI: 0.24–0.46) and decreased the adverse reactions (OR: 0.05; 95% CI: 0.02–0.01) and the recurrence rate (OR: 0.30; 95% CI: 0.16–0.57). However, there was no significant improvement in the cough symptom score comparing ZSS with western medicine.Conclusions. This meta-analysis shows that ZSS has significant additional benefits and relative safety in treating cough. However, more rigorously designed investigations and studies, with large sample sizes, are needed because of the methodological flaws and low quality of the included trials in this meta-analysis.


---

## Body

## 1. Introduction

Cough is the most common symptom among individuals seeking medical care. According to the duration, cough is divided into three types: acute, subacute, and chronic [1]. Acute cough (less than 3 weeks in duration) is the most predominant symptom of common cold or acute viral upper respiratory tract infection (URTI) [2, 3]. Acute cough from the common cold is usually transient and minor, but it may be life-threatening when it is caused by a serious illness [2]. Dyspnea, tachypnea, thoracic pain, hemoptysis, a severely worsened general state, and changes in vital signs are the major danger signs of acute cough [4]. Cough lasting from 3 to 8 weeks is categorized as subacute cough [5]. Postinfectious cough (PIC) is the most common cause of subacute cough [5]. Chronic cough is described as a cough that persisted for more than 8 weeks in adults [6] and more than 4 weeks in children (age < 15 years) [7]. Gastroesophageal reflux disease (GERD), asthma syndromes, smoker’s cough, nonasthmatic eosinophilic bronchitis, and upper airway cough syndrome (UACS) associated with postnasal drip (rhinitis or rhinosinusitis) are the most common conditions associated with chronic cough in adults who are nonsmokers and are not receiving therapy with angiotensin converting enzyme (ACE) inhibitor [6, 8–10]. Unexplained chronic cough should be diagnosed as chronic cough with no etiology identified after evaluation and supervised therapeutic trial(s) that follow published best-practice guidelines [11].Recent guidelines have attempted to provide directions in the treatment and management of cough. Patients with acute cough associated with the common cold can be treated with first-generation antihistamine/decongestant (A/D) preparation, expectorants, or mucolytics [3, 8]. Acute cough accompanying a cold or acute bronchitis/sinusitis usually resolves without any specific medicinal treatment. Any antibiotic treatment of uncomplicated upper respiratory tract infections should be avoided according to the guideline [4]. Although the inhaled ipratropium or inhaled corticosteroids (ICSs) may be useful for PIC, the optimal treatment is not known [8, 57]. Cough variant asthma (CVA) should be initially treated with inhaled bronchodilators and ICSs [8]. Dietary and lifestyle modification, acid suppression therapy, and prokinetic therapy are recommended in patients with chronic cough due to GERD [8]. Current recommendations on managing UACS include A/D or intranasal corticosteroids [6]. Multimodality speech pathology therapy and therapeutic trial of gabapentin are recommended for adults with unexplained chronic cough [11].ZSS, a formula originating from Qing Dynasty, is commonly used in treating cough nowadays. Tan et al. [58], Zhang [59], and Meng et al. [60], respectively, reported that ZSS is the most frequently used formula in the treatment of PIC and CVA. ZSS is composed of seven herbs:Platycodon grandiflorum, Fine Leaf Schizonepeta herb, Tatarian Aster root, Sessile Stemona root/Japanese Stemona root/Tuber Stemona root, Willowleaf Swallowwort Rhizome, tangerine peel, and liquorice root. According to the theory of TCM, ZSS could loose the evil Qi and calm the lung Qi. Compared to its counterparts, ZSS is peaceful and gentle, not too cold or hot.Modified Zhi Sou San (MZSS) could improve the symptoms of chronic obstructive pulmonary disease (COPD) in rats of northwest China with cold dryness syndrome and delay the velocity of decreased lung function [61]. An experiment showed that the antiasthmatic mechanisms of MZSS were related to its significant reduction in contents of endothelin-1 and nitric oxide, eosinophilia, and the damage of lung tissue [62].Several systematic reviews and meta-analyses showed that ZSS might be effective in treating diseases-induced cough (including PIC, CVA, and laryngeal cough) [63–65]. Jing et al. reported that MZSS or MZSS combined with western medicine had better safety and efficacy than western medicine alone in treating PIC [63]. ZSS or ZSS combined with western medicine had superior effect and lower recurrence rate than western medicine alone in treating CVA [64]. Wang et al. reported that, compared with western medicine, ZSS had good efficacy and less adverse reactions in treating laryngeal cough [65]. Although the aforementioned reviews and meta-analyses elaborated that ZSS was more effective and safe than western medicine in treating diseases-induced cough, whether ZSS is the alternative medicine in treating cough is not confirmed. More trials and evidences are needed. So this meta-analysis was aimed at summarizing and evaluating the evidence from RCTs and determining whether ZSS is more effective and safer than western medicine in the treatment of cough.


## 2. Methods

### 2.1. Research Protocol

This meta-analysis is reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.


### 2.2. Databases and Search Strategies

We searched relevant articles up to 5 March 2017 in seven electronic databases: CENTRAL, MEDLINE, and PubMed in English and CNKI, VIP, CBM, and Wanfang Data in Chinese. The search terms used for databases were as follows: (cough or cough∗) for cough AND (zhisousan or zhisou san or zhisou powder) for ZSS AND randomized or controlled or clinical research.


### 2.3. Eligibility Criteria

Studies included had to meet the following criteria: (a) types of studies: any RCTs with ZSS or MZSS administrated orally in patients with cough were eligible, regardless of blinding; (b) types of participants: any patients diagnosed with cough regardless of sex, age, country, or underlying disease were included; (c) types of interventions: any variants of ZSS regardless of the herbs in the ZSS archetype replaced, added, or removed were included; the control group was taking the western medicine; (d) types of outcomes: the primary outcome was the total effective rate (clinical cure rate plus obvious cure rate plus showing effective rate). The clinical efficacy classified as clinical cure, obvious cure, and showing effective and not effective rate was based on the guiding principle of clinical research on new drugs of TCM and/or the diagnostic criteria of TCM syndrome. The secondary outcomes were the score of TCM symptom, cough symptom score (such as cough diary or visual analog scale), the adverse reactions, the pulmonary function test results, and the recurrence rate.


### 2.4. Study Selection and Data Extraction

Two independent investigators (Ningchang Cheng and Jia Zhu) screened the titles and abstracts of the searched articles. The trials obviously not meeting the inclusion criteria were excluded. We emailed the corresponding authors of the trials which possibly meet the inclusion criteria to ensure that the included trials were RCTs. Any disagreements were dissolved by consensus and discussions. All articles included were judged by the third reviewer (Pinpin Ding). Data extracted included the authors, year of publication, country, sample size, participants (mean age, cough duration), cough inducing disease, details of ZSS interventions, details of control inventions, treatment duration, outcome measurements, and adverse events [66].


### 2.5. Assessment of Risk of Bias

According to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.0.2), the risk of bias was assessed in seven domains, such as random sequence generation and allocation concealment for selection bias, blinding of participants and personnel for performance bias, blinding of outcome assessment for detection bias, incomplete outcome data for attrition bias, selective outcome reporting for reporting bias, and other sources of bias.


### 2.6. Data Analysis

Review Manager Software (Version 5.3, Copenhagen, the Nordic Cochrane Centre, the Cochrane Collaboration, 2014) was used for data analysis. Heterogeneity between similar studies is evaluated by chi-square test andI2 statistic. There is moderate heterogeneity between studies, if P<0.05 and I2>50%, and sensitivity analysis is needed. The enumeration data is evaluated as dichotomous data and expressed as odds ratio (OR) with 95% confidence interval (CI). The measurement data is evaluated as continuous data and expressed as mean difference (MD) with 95% CI. Statistical significant difference was considered as P<0.05.


## 2.1. Research Protocol

This meta-analysis is reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.


## 2.2. Databases and Search Strategies

We searched relevant articles up to 5 March 2017 in seven electronic databases: CENTRAL, MEDLINE, and PubMed in English and CNKI, VIP, CBM, and Wanfang Data in Chinese. The search terms used for databases were as follows: (cough or cough∗) for cough AND (zhisousan or zhisou san or zhisou powder) for ZSS AND randomized or controlled or clinical research.


## 2.3. Eligibility Criteria

Studies included had to meet the following criteria: (a) types of studies: any RCTs with ZSS or MZSS administrated orally in patients with cough were eligible, regardless of blinding; (b) types of participants: any patients diagnosed with cough regardless of sex, age, country, or underlying disease were included; (c) types of interventions: any variants of ZSS regardless of the herbs in the ZSS archetype replaced, added, or removed were included; the control group was taking the western medicine; (d) types of outcomes: the primary outcome was the total effective rate (clinical cure rate plus obvious cure rate plus showing effective rate). The clinical efficacy classified as clinical cure, obvious cure, and showing effective and not effective rate was based on the guiding principle of clinical research on new drugs of TCM and/or the diagnostic criteria of TCM syndrome. The secondary outcomes were the score of TCM symptom, cough symptom score (such as cough diary or visual analog scale), the adverse reactions, the pulmonary function test results, and the recurrence rate.


## 2.4. Study Selection and Data Extraction

Two independent investigators (Ningchang Cheng and Jia Zhu) screened the titles and abstracts of the searched articles. The trials obviously not meeting the inclusion criteria were excluded. We emailed the corresponding authors of the trials which possibly meet the inclusion criteria to ensure that the included trials were RCTs. Any disagreements were dissolved by consensus and discussions. All articles included were judged by the third reviewer (Pinpin Ding). Data extracted included the authors, year of publication, country, sample size, participants (mean age, cough duration), cough inducing disease, details of ZSS interventions, details of control inventions, treatment duration, outcome measurements, and adverse events [66].


## 2.5. Assessment of Risk of Bias

According to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.0.2), the risk of bias was assessed in seven domains, such as random sequence generation and allocation concealment for selection bias, blinding of participants and personnel for performance bias, blinding of outcome assessment for detection bias, incomplete outcome data for attrition bias, selective outcome reporting for reporting bias, and other sources of bias.


## 2.6. Data Analysis

Review Manager Software (Version 5.3, Copenhagen, the Nordic Cochrane Centre, the Cochrane Collaboration, 2014) was used for data analysis. Heterogeneity between similar studies is evaluated by chi-square test andI2 statistic. There is moderate heterogeneity between studies, if P<0.05 and I2>50%, and sensitivity analysis is needed. The enumeration data is evaluated as dichotomous data and expressed as odds ratio (OR) with 95% confidence interval (CI). The measurement data is evaluated as continuous data and expressed as mean difference (MD) with 95% CI. Statistical significant difference was considered as P<0.05.


## 3. Results

### 3.1. Characteristics of the Included Studies

We identified 905 articles through electronic searching. After duplicates were removed, 263 records were screened. The full texts of 141 studies were assessed for eligibility after screening the titles and abstracts. 95 studies were excluded with reasons of full text being unavailable, not being RCTs, the controlled group not taking western medicine, and not relevant trials. Finally, 46 studies [12–56, 67] were included in this meta-analysis. A flowchart in the form of PRISMA is presented in Figure 1.Figure 1
Flowchart of literature searching.All the included trials originated from China and were published from 2004 to 2016. The total number of participants analyzed in the meta-analysis was 4007, of which 2077 received ZSS or MZSS, while 1930 received western medicine alone. The baseline characteristics of the included trials were shown in Table1.Table 1
Baseline characteristics of the included trials.
Author
Year
Country
Cough inducing disease
Sample size (I/C)
Intervention group
Control group
Age (years)(I/C)
Cough duration(I/C)
Intervention duration
Outcome measurements
Dong [12]
2014
China
Postsurgical cough
52/53
ZSS
Gentamicin +α-chymotrypsin
32–65
NR
3 d
①
Cai [13]
2013
China
PIC
36/36
MZSS
Ketotifen or ambroxol
6–15/7–19
NR
5 d
①
Cai [14]
2011
China
PIC
30/30
MZSS
Meptin + ketotifen + azithromycin
18–60/21–55
21–55 d/22–54 d
7 d
①
Cao [15]
2011
China
PIC
30/27
ZSS
Cephalexin + compound guaiacol potassium oral solution
3–8/4–10
15 d–1 y/10 d–10 m
7 d
①
Jin [16]
2016
China
PIC
40/40
MZSS
Pentoxyverine + loratadine
50.08
±
7.82
/
49.85
±
7.85
24.53
±
8.40
d
/
23.88
±
7.90
d
10 d
①
Ju [17]
2010
China
PIC
56/56
MZSS
Chlorphenamine maleate
37.5
l
±
9.47
/
40.18
±
10.56
40.5
±
11.5
d
/
41.2
±
12.7
d
15 d
① + ②
Kan [18]
2010
China
PIC
30/30
MZSS
Dextromethorphan + chlorphenamine maleate
45.47
±
8.36
/
44.59
±
8.72
4.8
±
1.2
w
k
/
4.6
±
1.5
w
k
10 d
①
Kan [19]
2011
China
PIC
33/32
MZSS
Roxithromycin id
2–10/2–10
4 wk–3 m/4 wk–3 m
14 d
①
Li [20]
2013
China
PIC
30/30
MZSS
Asmeton
32.19
±
5.86
/
33.35
±
5.72
36.6
±
6.9
d
/
33.2
±
7.5 d
7 d
① + ③
Liang [21]
2014
China
PIC
84/84
MZSS
Pentoxyverine
32.1
±
1.7
/
31.9
±
2.4
14.3
±
2.0
d
/
14.0
±
1.9
d
NR
① + ③
Liu and Qiu [22]
2012
China
PIC
38/40
MZSS
Pentoxyverine + chlorphenamine maleate
19–53/18–55
3–8 wk
NR
① + ③
Liu [23]
2014
China
PIC
68/64
MZSS
Ketotifen + carbetapentane citrate
36.0
±
6.8
/
38.0
±
7.5
33.0
±
7.5
d
/
35.0
±
8.5
d
10 d
①
Lu [24]
2012
China
PIC
43/43
MZSS
Ketotifen + meptin + azithromycin
34.3
±
1.4
38
±
2.1
d
7 d
①
Qiu [25]
2012
China
PIC
28/28
MZSS
Chlorphenamine maleate + cartussin
22–55/20–60
19–49 d/23–46 d
15 d
①
Qiu [26]
2011
China
PIC
82/78
MZSS
Dextromethorphan + loratadine
33.5
±
8.6
/
34.3
±
8.8
18
±
3.0
d
/
17.6
±
2.0
d
7 d
① + ③
Qiu [27]
2012
China
PIC
35/30
MZSS
Compound pholcodine syrup + asmeton + azithromycin
14–65/15–65
NR
3 d
①
Sun [28]
2011
China
PIC
58/52
MZSS
Chlorpheniramine maleate + methyl bromide
19–57/20–58
14–40 d/16–41 d
7 d
①
Tao [29]
2011
China
PIC
30/30
MZSS
Pseudoephedrine hydrochloride sustained release capsules
40.2
±
8.7
/
39.5
±
7.5
40.5
±
13
d
/
42.8
±
10.0
d
7 d
① + ②
Zhu [30]
2010
China
PIC
62/30
MZSS
Azithromycin
2 m–13/5 m–13
2–4 d/1–5 d
3 wk
①
Chen [31]
2004
China
Laryngeal cough
39/39
MZSS
Roxithromycin id + Zhikelu
5–87/7–82
5 d–2 y/3 d–1.5 y
5 d
①
Fang [32]
2014
China
Laryngeal cough
43/43
MZSS
Setastine + carbetapentane citrate + new bromide
40/41
3–12 wk/3–12 wk
14 d
①
Hu [33]
2013
China
Laryngeal cough
59/54
MZSS
Budesonide
34–63/32–64
3–8 wk/3–7.3 wk
7 d
① + ⑤
Huang [34]
2013
China
Laryngeal cough
60/60
MZSS
Cefuroxime axetil + phenergan syrup
16–64/17–65
7 d–3 m/7 d–3 m
10 d
① + ③ + ⑤
Liu [35]
2004
China
Laryngeal cough
72/38
MZSS
Amoxicillin or cefradine + phenergan cough syrup
31.3
±
2.1
/
30.1
±
2.3
42
±
2.3
d
/
43.3
±
6.7
d
4 d
①
Gong [36]
2007
China
CVA
40/40
MZSS
Ketotifen + doxofylline + salbutamol aerosol
41.3
±
10.3
/
38.5
±
11.8
2–36 m/2–30 m
28 d
① + ④
Lu [37]
2007
China
CVA
35/34
MZSS
Terbutaline + cetirizine
9.6/9.2
1.3 m/1.4 m
14 d
①
Liu [35]
2012
China
CVA
28/25
MZSS
Shah Mette Lo fluticasone propionate
43.79
±
12.58
/
42.16
±
10.77
3.42
±
2.17
m
/
3.55
±
2.29
m
14 d
① + ②
Qu [38]
2006
China
CVA
30/30
MZSS
Terbutaline
38.2
±
12.5
/
40.3
±
13.2
7.5
±
8.5
m
/
8.0
±
7.0
m
30 d
① + ④
Tao [39]
2014
China
CVA
55/55
MZSS
Montelukast sodium + budesonide aerosol
2–11/2.5–12
3–33 m/4–36 m
4 wk
①
Wang [40]
2011
China
CVA
60/60
MZSS
Conventional treatment for cough
2–9/2.5–10
NR
10 d
①
Yu et al. [41]
2016
China
CVA
52/52
MZSS
Shah Mette Lo fluticasone powder
40.9
±
6.8
/
41.5
±
7.2
8.5
±
2.2
m
/
8.2
±
2.4
m
30 d
① + ② + ④
Zhang [42]
2009
China
CVA
30/30
MZSS
Ceftazidime + dexamethasone
2–66
NR
14 d
① + ②
Shao [43]
2004
China
Cough
60/48
MZSS
Cefradine
14–66/12–62
NR
14 d
①
Cai [44]
2011
China
Chronic cough
24/24
MZSS
Conventional treatment for cough
26–70/20–65
8–36 wk/10–42 wk
14 d
①
Dai et al. [45]
2015
China
Chronic cough
26/26
MZSS
Desloratadine + ambroxol
37.83
±
10.43
/
36.40
±
11.89
28.55
±
26.71
w
k
/
34.73
±
24.17
w
k
14 d
①
Huang [46]
2014
China
Chronic cough
45/45
MZSS
Chlorphenamine + aminophylline + ambroxol
24–75
8 wk–2 y
14 d
① + ③
Qiao [47]
2016
China
Chronic cough
40/40
MZSS
Cefuroxime axetil + ambroxol + dextromethorphan
54.6
±
7.9
3.3
±
1.6 y
1 m
① + ③
Tao [48]
2013
China
Chronic cough
40/40
MZSS
Azithromycin + ambroxol
20–76
NR
7 d
①
Wang and Guo [49]
2016
China
Chronic cough
50/50
MZSS
Chlorpheniramine maleate + salbutamol + methyl bromide
4.65
±
1.94
/
5.46
±
2.53
NR
7 d
①
Yang [50]
2015
China
Chronic cough
47/47
MZSS
Asmeton
41.6
±
5.7
10.4
±
1.9
7 d
① + ③
Ye [51]
2009
China
Chronic cough
30/30
MZSS
Asmeton
19–46
NR
7 d
①
Zhang [52]
2016
China
Chronic cough
44/44
MZSS
Ambroxol
50
±
2.96
/
51
±
2.63
NR
14 d
① + ⑤
Dang and Yang [53]
2008
China
Allergic cough
38/38
MZSS
Ketotifen + aminophylline
2–12/2–12
1–6.6 m/1–5.9 m
7 d
①
Zhang [54]
2014
China
Allergic cough
25/25
MZSS
Terbutaline
6.25
±
3.05
/
6.05
±
3.12
8.09
±
15.45
m
/
7.86
±
15.36
m
4 wk
① + ③
Hu [55]
2015
China
Acute cough
60/60
ZSS
Asmeton
37
±
11
/
36
±
10
18
±
6
d
/
16
±
7
d
14 d
①
Huang [56]
2011
China
Acute cough
80/40
MZSS
Amoxicillin
19–35/20–34
0.5–7 d/0.5–6.5 d
3 d
①
y, year; m, month; wk, week; d, day; NR: not reported.Note. ① The total effective rate, ② cough symptom score, ③ the adverse reactions, ④ the pulmonary function test results, and ⑤ the recurrence rate.In the final selected studies, postsurgical cough accounted for one study [12], cough accounted for one study [43], allergic cough accounted for two studies [53, 54], acute cough accounted for one study [56], laryngeal cough accounted for six studies [31–35, 55], CVA accounted for eight studies [36–42, 67], chronic cough accounted for nine studies [44–52], and PIC accounted for eighteen studies [13–30].


### 3.2. The Total Effective Rate

All trials finally selected reported data on total clinical response rate [12–56, 67]. As for the fact that there was no significant heterogeneity (I2=0%; P=0.94), a random-effects model was applied (Figure 2). The meta-analysis showed that a significant improvement in the total effective rate (OR: 4.45; 95% CI: 3.62–5.47) was observed when comparing ZSS to western medicine alone.Figure 2
The effective rate comparing ZSS to western medicine alone.


### 3.3. Cough Symptom Score

Five trials reported data on cough symptom score [17, 29, 41, 42, 67]. After sensitivity analysis, a trial [17] was excluded. As for the fact that there was no significant heterogeneity (I2=0%; P=0.53), the meta-analysis showed that there was no significant improvement in the cough symptom score (OR: −0.72; 95% CI: −0.79–−0.65).


### 3.4. The Adverse Reactions

Nine trials mentioned the adverse reactions as the secondary outcome [20–22, 26, 34, 46, 47, 50, 54]. As is shown in Figure 3, a random-effects model was applied; there was no significant heterogeneity (I2=43%; P=0.09). The meta-analysis showed that a significant decrease in the adverse reactions (OR: 0.05; 95% CI: 0.02–0.01) was observed when comparing ZSS to western medicine alone.Figure 3
The adverse reactions comparing ZSS to western medicine alone.


### 3.5. The Pulmonary Function Test Results

Three trials provided data on the pulmonary function test results [36, 38, 41]. Two trials reported FEV1 (L) [38, 41]. The meta-analysis with random-effects model showed that ZSS significantly improved the pulmonary function in terms of FEV1 (I2=0%; P=0.46; OR: 0.35; 95% CI: 0.24–0.46) in comparison to western medicine alone (Figure 4).Figure 4
The pulmonary function test results comparing ZSS to western medicine alone.


### 3.6. The Recurrence Rate

There were three studies that talked about the recurrence rate [33, 34, 52]. Results (Figure 5) indicated that ZSS obviously decreased the recurrence rate compared with western medicine (I2=0%; P=0.55; OR: 0.30; 95% CI: 0.16–0.57).Figure 5
The recurrence rate comparing ZSS to western medicine alone.


### 3.7. Assessing the Risk of Bias of the Included Studies

The risk of bias of the finally included trials was not low. The selection bias was high due to the fact that wrong methods were applied in random sequence generation. Because multiple studies failed in blinding of participant and outcome assessment, the performance and detection biases were high (Figures6 and 7) (+ indicates low risk of bias, − indicates high risk of bias, and ? indicates unclear risk of bias).Figure 6
Risk of bias graph of the included trials.Figure 7
Risk of bias summary of the included trials.


## 3.1. Characteristics of the Included Studies

We identified 905 articles through electronic searching. After duplicates were removed, 263 records were screened. The full texts of 141 studies were assessed for eligibility after screening the titles and abstracts. 95 studies were excluded with reasons of full text being unavailable, not being RCTs, the controlled group not taking western medicine, and not relevant trials. Finally, 46 studies [12–56, 67] were included in this meta-analysis. A flowchart in the form of PRISMA is presented in Figure 1.Figure 1
Flowchart of literature searching.All the included trials originated from China and were published from 2004 to 2016. The total number of participants analyzed in the meta-analysis was 4007, of which 2077 received ZSS or MZSS, while 1930 received western medicine alone. The baseline characteristics of the included trials were shown in Table1.Table 1
Baseline characteristics of the included trials.
Author
Year
Country
Cough inducing disease
Sample size (I/C)
Intervention group
Control group
Age (years)(I/C)
Cough duration(I/C)
Intervention duration
Outcome measurements
Dong [12]
2014
China
Postsurgical cough
52/53
ZSS
Gentamicin +α-chymotrypsin
32–65
NR
3 d
①
Cai [13]
2013
China
PIC
36/36
MZSS
Ketotifen or ambroxol
6–15/7–19
NR
5 d
①
Cai [14]
2011
China
PIC
30/30
MZSS
Meptin + ketotifen + azithromycin
18–60/21–55
21–55 d/22–54 d
7 d
①
Cao [15]
2011
China
PIC
30/27
ZSS
Cephalexin + compound guaiacol potassium oral solution
3–8/4–10
15 d–1 y/10 d–10 m
7 d
①
Jin [16]
2016
China
PIC
40/40
MZSS
Pentoxyverine + loratadine
50.08
±
7.82
/
49.85
±
7.85
24.53
±
8.40
d
/
23.88
±
7.90
d
10 d
①
Ju [17]
2010
China
PIC
56/56
MZSS
Chlorphenamine maleate
37.5
l
±
9.47
/
40.18
±
10.56
40.5
±
11.5
d
/
41.2
±
12.7
d
15 d
① + ②
Kan [18]
2010
China
PIC
30/30
MZSS
Dextromethorphan + chlorphenamine maleate
45.47
±
8.36
/
44.59
±
8.72
4.8
±
1.2
w
k
/
4.6
±
1.5
w
k
10 d
①
Kan [19]
2011
China
PIC
33/32
MZSS
Roxithromycin id
2–10/2–10
4 wk–3 m/4 wk–3 m
14 d
①
Li [20]
2013
China
PIC
30/30
MZSS
Asmeton
32.19
±
5.86
/
33.35
±
5.72
36.6
±
6.9
d
/
33.2
±
7.5 d
7 d
① + ③
Liang [21]
2014
China
PIC
84/84
MZSS
Pentoxyverine
32.1
±
1.7
/
31.9
±
2.4
14.3
±
2.0
d
/
14.0
±
1.9
d
NR
① + ③
Liu and Qiu [22]
2012
China
PIC
38/40
MZSS
Pentoxyverine + chlorphenamine maleate
19–53/18–55
3–8 wk
NR
① + ③
Liu [23]
2014
China
PIC
68/64
MZSS
Ketotifen + carbetapentane citrate
36.0
±
6.8
/
38.0
±
7.5
33.0
±
7.5
d
/
35.0
±
8.5
d
10 d
①
Lu [24]
2012
China
PIC
43/43
MZSS
Ketotifen + meptin + azithromycin
34.3
±
1.4
38
±
2.1
d
7 d
①
Qiu [25]
2012
China
PIC
28/28
MZSS
Chlorphenamine maleate + cartussin
22–55/20–60
19–49 d/23–46 d
15 d
①
Qiu [26]
2011
China
PIC
82/78
MZSS
Dextromethorphan + loratadine
33.5
±
8.6
/
34.3
±
8.8
18
±
3.0
d
/
17.6
±
2.0
d
7 d
① + ③
Qiu [27]
2012
China
PIC
35/30
MZSS
Compound pholcodine syrup + asmeton + azithromycin
14–65/15–65
NR
3 d
①
Sun [28]
2011
China
PIC
58/52
MZSS
Chlorpheniramine maleate + methyl bromide
19–57/20–58
14–40 d/16–41 d
7 d
①
Tao [29]
2011
China
PIC
30/30
MZSS
Pseudoephedrine hydrochloride sustained release capsules
40.2
±
8.7
/
39.5
±
7.5
40.5
±
13
d
/
42.8
±
10.0
d
7 d
① + ②
Zhu [30]
2010
China
PIC
62/30
MZSS
Azithromycin
2 m–13/5 m–13
2–4 d/1–5 d
3 wk
①
Chen [31]
2004
China
Laryngeal cough
39/39
MZSS
Roxithromycin id + Zhikelu
5–87/7–82
5 d–2 y/3 d–1.5 y
5 d
①
Fang [32]
2014
China
Laryngeal cough
43/43
MZSS
Setastine + carbetapentane citrate + new bromide
40/41
3–12 wk/3–12 wk
14 d
①
Hu [33]
2013
China
Laryngeal cough
59/54
MZSS
Budesonide
34–63/32–64
3–8 wk/3–7.3 wk
7 d
① + ⑤
Huang [34]
2013
China
Laryngeal cough
60/60
MZSS
Cefuroxime axetil + phenergan syrup
16–64/17–65
7 d–3 m/7 d–3 m
10 d
① + ③ + ⑤
Liu [35]
2004
China
Laryngeal cough
72/38
MZSS
Amoxicillin or cefradine + phenergan cough syrup
31.3
±
2.1
/
30.1
±
2.3
42
±
2.3
d
/
43.3
±
6.7
d
4 d
①
Gong [36]
2007
China
CVA
40/40
MZSS
Ketotifen + doxofylline + salbutamol aerosol
41.3
±
10.3
/
38.5
±
11.8
2–36 m/2–30 m
28 d
① + ④
Lu [37]
2007
China
CVA
35/34
MZSS
Terbutaline + cetirizine
9.6/9.2
1.3 m/1.4 m
14 d
①
Liu [35]
2012
China
CVA
28/25
MZSS
Shah Mette Lo fluticasone propionate
43.79
±
12.58
/
42.16
±
10.77
3.42
±
2.17
m
/
3.55
±
2.29
m
14 d
① + ②
Qu [38]
2006
China
CVA
30/30
MZSS
Terbutaline
38.2
±
12.5
/
40.3
±
13.2
7.5
±
8.5
m
/
8.0
±
7.0
m
30 d
① + ④
Tao [39]
2014
China
CVA
55/55
MZSS
Montelukast sodium + budesonide aerosol
2–11/2.5–12
3–33 m/4–36 m
4 wk
①
Wang [40]
2011
China
CVA
60/60
MZSS
Conventional treatment for cough
2–9/2.5–10
NR
10 d
①
Yu et al. [41]
2016
China
CVA
52/52
MZSS
Shah Mette Lo fluticasone powder
40.9
±
6.8
/
41.5
±
7.2
8.5
±
2.2
m
/
8.2
±
2.4
m
30 d
① + ② + ④
Zhang [42]
2009
China
CVA
30/30
MZSS
Ceftazidime + dexamethasone
2–66
NR
14 d
① + ②
Shao [43]
2004
China
Cough
60/48
MZSS
Cefradine
14–66/12–62
NR
14 d
①
Cai [44]
2011
China
Chronic cough
24/24
MZSS
Conventional treatment for cough
26–70/20–65
8–36 wk/10–42 wk
14 d
①
Dai et al. [45]
2015
China
Chronic cough
26/26
MZSS
Desloratadine + ambroxol
37.83
±
10.43
/
36.40
±
11.89
28.55
±
26.71
w
k
/
34.73
±
24.17
w
k
14 d
①
Huang [46]
2014
China
Chronic cough
45/45
MZSS
Chlorphenamine + aminophylline + ambroxol
24–75
8 wk–2 y
14 d
① + ③
Qiao [47]
2016
China
Chronic cough
40/40
MZSS
Cefuroxime axetil + ambroxol + dextromethorphan
54.6
±
7.9
3.3
±
1.6 y
1 m
① + ③
Tao [48]
2013
China
Chronic cough
40/40
MZSS
Azithromycin + ambroxol
20–76
NR
7 d
①
Wang and Guo [49]
2016
China
Chronic cough
50/50
MZSS
Chlorpheniramine maleate + salbutamol + methyl bromide
4.65
±
1.94
/
5.46
±
2.53
NR
7 d
①
Yang [50]
2015
China
Chronic cough
47/47
MZSS
Asmeton
41.6
±
5.7
10.4
±
1.9
7 d
① + ③
Ye [51]
2009
China
Chronic cough
30/30
MZSS
Asmeton
19–46
NR
7 d
①
Zhang [52]
2016
China
Chronic cough
44/44
MZSS
Ambroxol
50
±
2.96
/
51
±
2.63
NR
14 d
① + ⑤
Dang and Yang [53]
2008
China
Allergic cough
38/38
MZSS
Ketotifen + aminophylline
2–12/2–12
1–6.6 m/1–5.9 m
7 d
①
Zhang [54]
2014
China
Allergic cough
25/25
MZSS
Terbutaline
6.25
±
3.05
/
6.05
±
3.12
8.09
±
15.45
m
/
7.86
±
15.36
m
4 wk
① + ③
Hu [55]
2015
China
Acute cough
60/60
ZSS
Asmeton
37
±
11
/
36
±
10
18
±
6
d
/
16
±
7
d
14 d
①
Huang [56]
2011
China
Acute cough
80/40
MZSS
Amoxicillin
19–35/20–34
0.5–7 d/0.5–6.5 d
3 d
①
y, year; m, month; wk, week; d, day; NR: not reported.Note. ① The total effective rate, ② cough symptom score, ③ the adverse reactions, ④ the pulmonary function test results, and ⑤ the recurrence rate.In the final selected studies, postsurgical cough accounted for one study [12], cough accounted for one study [43], allergic cough accounted for two studies [53, 54], acute cough accounted for one study [56], laryngeal cough accounted for six studies [31–35, 55], CVA accounted for eight studies [36–42, 67], chronic cough accounted for nine studies [44–52], and PIC accounted for eighteen studies [13–30].


## 3.2. The Total Effective Rate

All trials finally selected reported data on total clinical response rate [12–56, 67]. As for the fact that there was no significant heterogeneity (I2=0%; P=0.94), a random-effects model was applied (Figure 2). The meta-analysis showed that a significant improvement in the total effective rate (OR: 4.45; 95% CI: 3.62–5.47) was observed when comparing ZSS to western medicine alone.Figure 2
The effective rate comparing ZSS to western medicine alone.


## 3.3. Cough Symptom Score

Five trials reported data on cough symptom score [17, 29, 41, 42, 67]. After sensitivity analysis, a trial [17] was excluded. As for the fact that there was no significant heterogeneity (I2=0%; P=0.53), the meta-analysis showed that there was no significant improvement in the cough symptom score (OR: −0.72; 95% CI: −0.79–−0.65).


## 3.4. The Adverse Reactions

Nine trials mentioned the adverse reactions as the secondary outcome [20–22, 26, 34, 46, 47, 50, 54]. As is shown in Figure 3, a random-effects model was applied; there was no significant heterogeneity (I2=43%; P=0.09). The meta-analysis showed that a significant decrease in the adverse reactions (OR: 0.05; 95% CI: 0.02–0.01) was observed when comparing ZSS to western medicine alone.Figure 3
The adverse reactions comparing ZSS to western medicine alone.


## 3.5. The Pulmonary Function Test Results

Three trials provided data on the pulmonary function test results [36, 38, 41]. Two trials reported FEV1 (L) [38, 41]. The meta-analysis with random-effects model showed that ZSS significantly improved the pulmonary function in terms of FEV1 (I2=0%; P=0.46; OR: 0.35; 95% CI: 0.24–0.46) in comparison to western medicine alone (Figure 4).Figure 4
The pulmonary function test results comparing ZSS to western medicine alone.


## 3.6. The Recurrence Rate

There were three studies that talked about the recurrence rate [33, 34, 52]. Results (Figure 5) indicated that ZSS obviously decreased the recurrence rate compared with western medicine (I2=0%; P=0.55; OR: 0.30; 95% CI: 0.16–0.57).Figure 5
The recurrence rate comparing ZSS to western medicine alone.


## 3.7. Assessing the Risk of Bias of the Included Studies

The risk of bias of the finally included trials was not low. The selection bias was high due to the fact that wrong methods were applied in random sequence generation. Because multiple studies failed in blinding of participant and outcome assessment, the performance and detection biases were high (Figures6 and 7) (+ indicates low risk of bias, − indicates high risk of bias, and ? indicates unclear risk of bias).Figure 6
Risk of bias graph of the included trials.Figure 7
Risk of bias summary of the included trials.


## 4. Discussion

A wide variety of pharmacological agents have been used in treating cough, such as antibiotic, ketotifen, asmeton, dextromethorphan, and ICSs [68]. No matter what caused cough, those mentioned agents were broadly used in remedying cough. “Zhisou,” by its Chinese definition, means relieving cough. So ZSS is one formula that has the behavior of relieving cough and it is widely applied in China, Korea, and Japan. It is necessary and attractive to compare ZSS and western medicine commonly used in curing cough. This meta-analysis was aimed at evaluating the effect and safety between ZSS and aforementioned western medicines. However, we could not find any studies originating from Japan or Korea in those databases that we have searched. It may be due to the fact that the authors of this meta-analysis all come from China; they do not master Japanese language and Korean language.As we know, this meta-analysis is the first one about using ZSS in treating cough. This meta-analysis included studies of a wide range of conditions, such as acute cough, chronic cough, PIC, and CVA. The main findings of this meta-analysis are as follows: ZSS significantly improved the total effective rate and the pulmonary function in terms of FEV1, ZSS decreased the adverse reactions and the recurrence rate compared with western medicine, and ZSS appeared to be safe, well-tolerant, and more effective in treating cough.However, we should admit that several limitations exist concerning this study. Firstly and foremost, the sample sizes of RCTs were small and limited. So, it was difficult to find out the influence of contingency factors. Secondly, insufficient reporting of random sequence generation and allocation concealment were the major methodological flaws in most of the included trials, which could result in selection bias and decrease the reliability of the evidence. Thirdly, the overall methodological quality of included trials was low due to the lack of blinding of participants and personnel and outcome assessment. On the whole, the finally included studies failed to follow CONSORT guidelines for RCTs; the risk of bias assessment was assessed as high risk or unclear risk in a majority of the RCTs. Therefore, RCTs with high quality and large sample are required to be done in the future.



---

*Source: 9436352-2017-07-17.xml*